Clinical Trial: Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07593092) titled 'Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors' on May 11.

Brief Summary: The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer

Intervention: BIOLOGICAL: XmAb541

Monoclonal Bispecific Antibody

BIOLOGICAL: XmAb808

Monoclonal Bispecific Antibody

Recruitmen...